A phase Ib, multi-center, open-label dose escalation and expansion platform study of VAY736 as single agent and in combination with select antineoplastic agents in patients with non-Hodgkin Lymphoma (NHL) (NCT04903197)
CVAY736J12101
This trial is No longer recruiting
Registration number NCT04903197
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Maciej Tatarczuch
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR